Tag: Dravet syndrome

Approximately one-third of individuals with epilepsy do not achieve seizure control with older, traditional medications. This has driven the development of numerous newer drugs used for management of epilepsy, expanding treatment options for both drug-resistant and newly diagnosed patients. These newer antiepileptic drugs (AEDs) often offer better tolerability, more focused mechanisms, and fewer drug interactions.

In 2018, the U.S. Food and Drug Administration (FDA) approved stiripentol, marketed under the brand name Diacomit, for treating seizures associated with Dravet syndrome. This milestone confirmed that **is stiripentol available in the USA** for this specific, rare form of epilepsy.

Dravet syndrome is a rare form of epilepsy with an incidence of 1 per 20,000 to 40,000 births. So, what is the generic name for the drug stiripentol, a key medication used to manage it?

As of late 2025, there is currently no therapeutically equivalent generic version of the prescription medication Epidiolex available in the United States. This means patients must rely on the branded product, which is the only FDA-approved cannabidiol for treating specific seizure disorders.

According to the manufacturer, Biocodex, DIACOMIT (stiripentol) is an orphan medicinal product and is distributed exclusively through a specialty pharmacy, confirming it is a specialty drug. This classification significantly impacts how the medication is accessed and managed for patients with Dravet syndrome.

The U.S. Food and Drug Administration (FDA) first approved a prescription cannabidiol oral solution (Epidiolex®) in 2018 for treating specific, severe forms of epilepsy. This medication has since become a critical option for patients seeking relief from debilitating seizures, clarifying precisely what is cannabidiol oral solution used for.

DIACOMIT (stiripentol) is an anticonvulsant approved by the FDA for the treatment of seizures associated with Dravet syndrome. Specifically, it is used as an adjunctive, or add-on, therapy with clobazam to help manage the frequent and prolonged seizures that are characteristic of this rare and severe form of epilepsy.

Epidiolex is the only FDA-approved prescription medication containing cannabidiol (CBD) for treating specific, severe forms of epilepsy. To get Epidiolex, you must obtain a valid prescription from a healthcare provider, and it must be filled through a specialty pharmacy, as it is a highly regulated substance not available over-the-counter.

According to a pooled analysis of pivotal trials, stiripentol significantly reduced convulsive seizure frequency in up to 70% of patients with Dravet syndrome. So, **what is the drug stiripentol used for**? It is prescribed as an adjunctive treatment for seizures associated with this severe, genetic epilepsy.